ROS1 fusion

Cemiplimab is an immunotherapy drug used to treat advanced non-small cell lung cancer (NSCLC). ROS1 fusion is a genetic variant in NSCLC, while EGFR mutation and ALK fusion are two other common NSCLC genetic variants. (@forista8)

#ECRN-#ESRN conference. You got it @Latinamd In the presence of a ROS1 fusion, should change those green benefit signs for IO to yellow for “caution”! @karenkellymd @NaglaAKarimMD @triparnasen @BrainTumorDoc (@drgandara)

#lungcancer #NSCLC New published Article Sharing 🎉🎉Importance of ROS1 gene fusions in non-small cell lung cancer 👉https://t.co/SnjbJURwvn @PatelOncology @AboutLungCancer @lcrf_org @LungCancerFaces @IASLC @DrewMoghanaki @jillfeldman4 @drgandara @EGFRResisters (@cdrjournal)

#ASCO23 | Hall D1 | Sund 4:42pm CT Intracranial and Systemic Efficacy of Repotrectinib in Advanced ROS1 Fusion-positive (ROS1+) Non-small Cell Lung Cancer (NSCLC) and Central Nervous System Metastases (CNS mets) in the Phase 1/2 TRIDENT-1 @JessicaJLinMD ➡️ https://t.co/I4j2RKV3WG (@MGHCancerCenter)

In this episode, @NarjustFlorezMD discusses ROS+1 Fusions in #NSCLC, including diagnosis, treatment, & new exciting research w/guests Dr. Lorenza Landi (National Cancer Institute Regina Elena), & @ShirishGadgeel (Henry Ford Cancer Institute). Listen: https://t.co/Z2b48UUjWb #LCSM (@IASLC)

Excellent review to understand the biology of #ROS1 fusions and develop new tyrosine kinase inhibitors in patients with non-small cell #lungcancer. https://t.co/r3uLkw1lvr (@Dr_Ivanoncologo)

Case 2 also in @JCOPO_ASCO: Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion–Positive #PancreaticCancer https://t.co/jjGTpXZyvi (@Aiims1742)

Taletrictinib an impressive new player for treatment of NSCLC tumors with ROS1 fusion, longer follow is needed for this disease but clear activity after Crizotinib offers chances for sequencing TKIs therapy in this subset of lung cancer patients #ELCC23 ⁦@OncoAlert⁩ (@bmassutis)

Brigatinib in crizotinib-naive ROS1 fusion-positive NSCLC @JSMO_official by Dr. Toshiaki Takahashi. Brigatinib demonstrated ORR of 67.9% (90% CI, 50.6-82.1) and met the pre-planned threshold boundary. #JSMO2023 #LCSM (@HHorinouchi)

How do you address resistance to first-line ROS1 TKI therapy in ROS1 fusion-positive lung cancers? Tune in as @JessicaJLinMD from @MGHThoracicOnc discusses the framework for considering later-line strategies at #TTLC23 @IASLC #LCSM @ros1cancer @ros1dersuk @MGHCancerCenter (@IASLC)

This is exciting ROS1 fusions are noted in primary brain tumors need more than entrectinib and crizotinib (@shawnkothari)

In @CD_AACR: NVL-520 (@nuvalent) is a selective, TRK-sparing, brain-penetrant inhibitor of ROS1 fusions & secondary resistance mutations https://t.co/uPXvEgC17d Figure below shows response to NVL-520 in a patient with ROS1 fusion #LungCancer with secondary mutation on prior Rx. (@Aiims1742)

The novel brain-penetrant ROS1-selective inhibitor NVL-520 elicited clinical activity and was well tolerated in heavily pretreated patients with ROS1 fusion–positive NSCLC. @alexdrilon @MSKCancerCenter #lcsm https://t.co/jr3KnWhChn (@OncLive)

Dr. @JessicaJLinMD will provide the latest updates in the management of #ROS1 #RET #NTRK and #NRG1 fusion-positive lung cancer at #DCLung22 on Saturday, October 29, 2022. Get all of the latest updates in one place! Full agenda, faculty and registration at: https://t.co/rZMLIyUBL3 (@StephenVLiu)

Dr. @JessicaJLinMD will provide the latest updates in the management of #ROS1 #RET #NTRK and #NRG1 fusion-positive lung cancer at #DCLung22 on Saturday, October 29, 2022. Get all of the latest updates in one place! Full agenda, faculty and registration at: https://t.co/rZMLIyUBL3 (@StephenVLiu)

Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with #entrectinib 🔗https://t.co/zFBoMBzXX7 ✏️ @alexdrilon @rdoebele @barlesi @genentech @FoundationATCG @MSKCancerCenter @CUAnschutz #NTRK #NSCLC #cfDNA (@MolOncology)

Study suggests entrectinib prolongs survival in ROS1 #TKI naïve patients with ROS1 fusion-positive #NSCLC, with modest activity in patients with #CNS-only progression post-crizotinib 💊🫁 See the study by @alexdrilon, Salvatore Siena & colleagues ➡️ https://t.co/xGgYHOQyaE (@LungSummit)

Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with #entrectinib 🔗https://t.co/zFBoMBzXX7 ✏️ @alexdrilon @rdoebele @barlesi @genentech @FoundationATCG @MSKCancerCenter @CUAnschutz #NTRK #NSCLC #ctDNA (@MolOncology)

This is the second publication I’ve shared with @FordePatrick this month, the first shared our experience treating ALK or ROS1 fusion tumors (excluding lung cancer) with crizotinib as part of the NCI MATCH https://t.co/1Kz3RwJeR0 (@AMansfieldMD)

What's new in ROS1 fusion-positive cancers? @alexdrilon summarizes the latest data on emerging targeted therapies and includes updates for repotrectinib, taletrectinib, NVL-520, and combination lorlatinib and SHP2, MEK, and MET inhibitor programs. #TTLC22 #LCSM @sloan_kettering (@IASLC)

Expert review of ROS1-fusion+ nsclc by @DralexGva where he highlights the different options- crizotinib, ceritinib, entrectinib, lorlatinib, repotrectinib. Assessing for G2032R may help to guide choices #LCSM #LungSummit (@DrJNaidoo)

a. reactive alveolar type II pneumocytes in NSCLC cases (positive) b. known ROS1 positive NSCLC tissue (positive) c. cell lines known to express ROS1-fusions d. known ROS1 negative NSCLC e. all of the above (@RocheDiaUSA)

In our small validation with the Idylla Cartridge NTRK3 fusions are not well detected, specially in Thyroid Papillary Cancer were high levels of basal NTRK expresión can give a false negative result. Intreagued by this false +, ok in Met exon 14, ret fusión, Ros1 and Alk fusion (@GRecondoMD)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic <i>ROS1</i> Fusion–Positive Non–Small-Cell Lung Cancer https://t.co/LGH0mwxxZX Great publication and study led by my previous "fellow"! Great job, Rafal! (@fred_hirsch)

There is an important role in serial liquid biopsies in patients with ALK and ROS-1 fusions to identify resistance and choose properly subsequent therapy @ros1cancer @ALKLungCancer @alk_fusion @isliquidbiopsy @Guardant360CDx @GuardantHealth @gotoPER @MCIStrong @mhshospital (@LuisERaez1)

Excellent paper studying ROS1 protein expression and corresponding DNA alterations and fusions https://t.co/c3WyBJ5rIb @IASLC #LCSM (@maryjofidlerMD)

Review in @NatRevClinOncol on #ROS1 fusions. Even though this is a rare event, we can expect to see high RR and long DOR with #TargetedTherapy. Really important to test with complementary DNA & RNA testing in all pts with #NSCLC @alexdrilon @ros1cancer https://t.co/r50Rd2bj9y (@CharuAggarwalMD)

Repotrectinib gets Breakthrough Therapy Designation by the US FDA for TKI-naïve ROS1 fusion-positive lung cancers. Congratulations to the TRIDENT-1 investigators and patients. https://t.co/iNeyYviX4U (@alexdrilon)

Another targeted agent for NSCLCs with a ROS1-fusion: Repotrectinib (@DrJNaidoo)

#ESMO20 If you haven't strolled by our virtual poster (540P), here are outcomes with entrectinib by line of therapy in cancers with #NTRK fusions and in NSCLC with #ROS1 fusions, supporting its use irrespective of number of prior lines of therapy. @OncoAlert (@StephenVLiu)

#OncoAlert Case on #JTOCRR: #ROS1 fusion mediates resistance to osimertinib in #EGFR #NSCLC. While drivers are usually mutually exclusive at diagnosis, resistance to targeted agents repeatedly invokes the same pathways (MET, NRG, ROS1...) #LCSM @IASLC https://t.co/O2PlDSaOiH (@StephenVLiu)